Endocrinology
Clusterin is not essential for androgen-regulated regeneration of the prostate
Published in Gene Therapy Weekly, November 9th, 2006
"Inhibition of clusterin expression has been shown to enhance the sensitivity of prostate cancer cells to chemo and hormone therapy. Clusterin antisense oligonucleotides (ASOs) are currently in phase II human clinical trials for treatment of hormone refractory prostate cancer.
"However, the role of clusterin in androgen-regulated involution and regeneration of the normal prostate gland has not been established," wrote D. Fink and colleagues, University of British Columbia.
"Prostate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-11-09)
More Articles from Gene Therapy Weekly
- Cholangiocarcinoma
Cholangiocarcinoma cell growth inhibited by receptor ligand - Genetics & Genomics
MicroRNA expression detected by RNA oligonucleotide hybridization - Genetics & Genomics
Therapeutic exon skipping achieved in Duchenne muscular dystrophy - RNA Interference
RNA interference-mediated enzyme silencing achieves therapeutic benefit - Vector Development
Lentiviral vector may be used to study and treat proliferative diseases - Cancer Gene Therapy
Reports outline cancer gene therapy research from West Virginia University, Mary Babb Randolph Cancer Center - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
